Method of treatment of dopamine-related dysfunction

a dopamine receptor and dopamine-related technology, applied in the direction of aerosol delivery, drug composition, inorganic non-active ingredients, etc., can solve the problems of insufficient dopaminergic activity of parkinson's disease, eventual loss of efficacy, dyskinesia, etc., to prevent the induction of tolerance and high affinity
US20050232870A1Inactive Publication Date: 2005-10-20PURDUE RES FOUND & UNIV OF NORTH CAROLINA AT CHAPEL HILL
3 Cites 4 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
PURDUE RES FOUND & UNIV OF NORTH CAROLINA AT CHAPEL HILL
Publication Date
2005-10-20
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to the treatment of dopamine-related dysfunction using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “off-period.” The D1 agonist concentration is reduced during the “off-period” to obtain a plasma concentration of agonist that suboptimally activates D1 dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises the steps of periodically administering to a patient a full D1 agonist with a half-life of up to about 6 hours at a dose resulting in a first plasma concentration of agonist capable of activating D1 dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 hours to obtain a second lower plasma concentration of agonist that results in suboptimal activation of D1 dopamine receptors for a period of time sufficient to prevent induction of tolerance.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60 / 261,889, filed Jan. 16, 2001 expressly incorporated by reference herein.FIELD OF THE INVENTION

[0002] The present invention relates to the treatment of disorders resulting from dopamine-related dysfunction using full D1 dopamine receptor agonists. More particularly, the invention relates to using full D1 dopamine receptor agonists in an intermittent dosing protocol to treat disorders resulting from dopamine-related dysfunction. BACKGROUND AND SUMMARY OF THE INVENTION

[0003] Dopamine is a neurotransmitter in the central nervous system that has been implicated in the etiology and treatment of several neurological and psychiatric disorders, such as schizophrenia, narcolepsy, restless leg syndrome, and Parkinson's disease, and of other disorders such as shock, including septic shock, congestive heart failure, arrhythmias, hypotension, and hypert...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More